Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00033202
Status:
COMPLETED
Last Update Posted:
2009-06-03
First Post:
2002-04-09
Brief Title:
This is an Early Study to Investigate the Effect of Gimatecan in Adults With Solid Tumor
Sponsor:
Sigma-Tau Research Inc
Organization:
Sigma-Tau Research Inc
Study Overview
Official Title:
Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Gimatecan is sigma-tau Researchs new potent oral Topoisomerase I inhibitor Drugs in this class play a crucial role in destroying DNA replication in tumors We are conducting this study to determine the Maximum Tolerated Dose of our compound when given as a capsule rather than by intravenous injection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None